NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients
Publication
, Conference
Harrison, SA; Abdelmalek, MF; Trotter, JF; Paredes, AH; Arnold, HL; Kugelmas, M; Bashir, MR; Ling, L; Rossi, SJ; DePaoli, AM; Rinella, ME; Loomba, RS
Published in: Journal of Hepatology
2017
Duke Scholars
Published In
Journal of Hepatology
DOI
ISSN
0168-8278
Publication Date
2017
Volume
66
Issue
1
Start / End Page
S92 / S93
Publisher
Elsevier BV
Related Subject Headings
- Gastroenterology & Hepatology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, S. A., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., … Loomba, R. S. (2017). NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. In Journal of Hepatology (Vol. 66, pp. S92–S93). Elsevier BV. https://doi.org/10.1016/s0168-8278(17)30448-8
Harrison, S. A., M. F. Abdelmalek, J. F. Trotter, A. H. Paredes, H. L. Arnold, M. Kugelmas, M. R. Bashir, et al. “NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients.” In Journal of Hepatology, 66:S92–93. Elsevier BV, 2017. https://doi.org/10.1016/s0168-8278(17)30448-8.
Harrison SA, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, et al. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. In: Journal of Hepatology. Elsevier BV; 2017. p. S92–3.
Harrison, S. A., et al. “NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients.” Journal of Hepatology, vol. 66, no. 1, Elsevier BV, 2017, pp. S92–93. Crossref, doi:10.1016/s0168-8278(17)30448-8.
Harrison SA, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Ling L, Rossi SJ, DePaoli AM, Rinella ME, Loomba RS. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. Journal of Hepatology. Elsevier BV; 2017. p. S92–S93.
Published In
Journal of Hepatology
DOI
ISSN
0168-8278
Publication Date
2017
Volume
66
Issue
1
Start / End Page
S92 / S93
Publisher
Elsevier BV
Related Subject Headings
- Gastroenterology & Hepatology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences